Ongoing trials:

First line of treatment

  • Ixazomib-Revlimid-Dexamethason in first line for the young
  • Daratumumab vs observation in smouldering myeloma
  • KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
  • HOVON129 - Treatment of primary plasma cell leukemia

Relapse or refractory, patient not eligible for ASCT

  • Panorama 3: Panobinostat-Velcade-Dexamethason randomized to different doses in relapse treatment
  • Melflufen vs Pomalidomide in relapsed myeloma
  • Cobimetinib +/- venetoclax +/- atezolizumab in relapsed myeloma
  • Ixazomib vs Pomalidomide in relapsed myeloma
  • Venetoclax for patients with 11;14-translocation at relapse
  • Phase-4-study on treatment with filzomib in routine practice

Upcoming trials:

  • Hovon147 - Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
  • bb2121 - A phase 3, multicenter, randomized, openlabel study to compare the efficacy and safety of BB2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM) (KarMMa-3)
  • Cooral - Cryoprevention of chemotherapy-induced oral mucositis after autologous stem cell transplantation, a randomized study
  • Titanium1 – Phase 1/2 open-label trial of tinostamustine conditioning and autologous stem cell transplantation for salvage treatment in relapsed/refractory multiple myeloma
  • Perseus - A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy
Page visits: 3133